AUTHOR=Zhou Zhou , Plug Leonie G. , Patente Thiago A. , de Jonge-Muller Eveline S. M. , Elmagd Amir Abou , van der Meulen-de Jong Andrea E. , Everts Bart , Barnhoorn Marieke C. , Hawinkels Lukas J. A. C. TITLE=Increased stromal PFKFB3-mediated glycolysis in inflammatory bowel disease contributes to intestinal inflammation JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.966067 DOI=10.3389/fimmu.2022.966067 ISSN=1664-3224 ABSTRACT=
Inflammatory bowel disease (IBD) is a chronic relapsing inflammation of the intestinal tract with currently not well-understood pathogenesis. In addition to the involvement of immune cells, increasing studies show an important role for fibroblasts in the pathogenesis of IBD. Previous work showed that glycolysis is the preferred energy source for fibroblasts in fibrotic diseases. 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) is a key kinase supporting glycolysis. Increased expression of PFKFB3 in several cancers and inflammatory diseases has been previously reported, but the metabolic status of fibroblasts and the role of PFKFB3 in patients with IBD are currently unknown. Therefore, in this study, we evaluated the role of glycolysis and PFKFB3 expression in IBD. Single-sample gene set enrichment analysis (ssGSEA) revealed that glycolysis was significantly higher in IBD intestinal samples, compared to healthy controls, which was confirmed in the validation cohorts of IBD patients. Single-cell sequencing data indicated that PFKFB3 expression was higher in IBD-derived stromal cells.